Objective: Necrotizing autoimmune myopathy (NAM) is a rare side-effect of statin therapy. We report the case of a patient who developed statin-induced NAM with a review of the clinical presentation and management of this rare entity. The case illustrates the importance of including NAM in the differential diagnosis of persistent myopathy in a statin-exposed individual.
INTRODUCTION
Statins are the first line therapy for primary hypercholesterolemia to prevent atherosclerotic cardiovascular and cerebrovascular disease. The mechanism of action of statins involves inhibition of the 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) enzyme, which is the rate-limiting step of the cholesterol synthesis pathway (1) . Although statins are generally well-tolerated, musculoskeletal manifestations are well-recognized side-effects. This can range from myalgias and/or mild creatine kinase (CK) elevation to myotoxicity including self-limited myotoxicity, rhabdomyolysis, and the rare recently recognized side-effect of necrotizing autoimmune myopathy (NAM). NAM is a rare autoimmune condition which is characterized by proximal muscle weakness, elevated CK level, myopathic pattern on electromyography, and necrosis and inflammation seen on muscle biopsy, with elevation in anti-HMGCR antibodies (1, 2, 3, 4, 5) . It has also been reported in patients who are statin-naïve (1, 3, 4, 5) . Its distinguishing features from other musculoskeletal side-effects of statins are persistence of proximal muscle weakness and elevated CK level despite statin discontinuation, evidence of muscle necrosis, and elevated anti-HMGCR antibodies. The pathophysiology of NAM is poorly understood; however, it is hypothesized that the interaction between statins and HMGCR enables immunogenic HMGCR proteins to be expressed, which in turn triggers DOI:10.4158/ACCR-2019-0547 © 2019 AACE autoimmunity against the enzyme (1) . NAM is a condition which requires prompt diagnosis and timely management and should be included in the differential diagnosis for persistent myopathy in statin-exposed individuals despite stain discontinuation.
CASE REPORT
We report the case of a 74-year-old male with a past medical history of primary hypercholesterolemia and hypertension, who was referred to Endocrinology for management of hypercholesterolemia in the setting of a statin contraindication. His initial lipid panel revealed 
DISCUSSION
Statins are one of the most widely prescribed lipid-lowering medications which act by inhibiting the HMGCR enzyme, which is the key enzyme in the rate limiting-step in the cholesterol synthesis pathway (1) . According to the Canadian Cardiovascular Society and American College of Cardiology/American Heart Association guidelines, statins are the first-line therapy for primary hypercholesterolemia and prevention of atherosclerotic cardiovascular disease (7, 8) . Musculoskeletal side-effects are the most common reason for statin discontinuation, ranging from self-limited myalgias to myotoxicity, rhabdomyolysis, and rarely NAM (1, 6, 9) . These side-effects almost always subside with statin discontinuation, except NAM.
NAM is a rare side-effect of statins and is an autoimmune condition with a prevalence of 2-3 new cases for every 100,000 statin-exposed individuals (1, 6, 9) . It is associated with human leukocyte antigen (HLA) DRB1*11:01 in adults and DRB1*07:01 in children and it is due to the development of antibodies against HMGCR (1, 2, 6) . Anti-HMGCR antibodies were first discovered in 2010 by Mammen et al. and have a reported sensitivity and specificity of 94.4% and 99.3%, respectively (1, 2, 6, 9, 10) . NAM is characterized by persistent proximal lower limb weakness and CK elevation despite statin discontinuation, myopathic pattern on electromyography, and muscle necrosis and inflammation on muscle biopsy. Rheumatologic, neurologic, and metabolic causes of proximal lower limb muscle weakness or neuropathy should be ruled out, as described in the case presentation. There are no clinical trials to guide the management of statin-induced NAM, however immunosuppressive therapy is the cornerstone of DOI:10.4158/ACCR-2019-0547 © 2019 AACE treatment. Selva-O'Callaghan et al. report that IVIg appears to be the best option for treating statin-induced NAM as it is the only agent which has been proven effective for treating inflammatory myopathies (1). Nichols et al., on the other hand, discuss the use of IVIg only in cases which are refractory to immunosuppressive therapy or cases that are particularly severe at diagnosis (2) . Other immunosuppressive agents such as azathioprine and methotrexate have also been used with good effect, as well as calcineurin antagonists and mycophenolate mofetil less commonly (1, 2, 5) . Although a clear association between specific statins and the development of NAM has not been shown, previous reports have demonstrated a greater propensity with atorvastatin and simvastatin (2) . Our patient was prescribed three statins on four different occasions, and therefore it is difficult to ascertain whether any one statin, or rather multiple trials of different statins, predisposed him to develop NAM. It is also unclear why he was prescribed statins multiple times despite a clear history of myositis/rhabdomyolysis. Interestingly, NAM has also been shown to occur in patients with no prior statin exposure (1, 3) . In our case, the patient was tested for anti-HMGCR antibodies given several previous exposures to statins and persistence of proximal lower limb myopathy with no clear rheumatologic, metabolic, or neurologic diagnoses.
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are monoclonal antibodies which can be used as an alternate agent if statins are contraindicated, such as in the case of statin-induced NAM. PCSK9 is a protein which regulates LDL cholesterol levels via internalization and degradation of LDL receptors (LDLR), thereby reducing the number of LDLR available to bind LDL cholesterol (11) . PCSK9 inhibitors work by inhibiting PCSK9, which DOI:10.4158/ACCR-2019-0547 © 2019 AACE results in a greater number of LDLR available to bind LDL cholesterol and thereby reducing circulating LDL levels (11) . In patients with statin-induced NAM, PCSK9 inhibitors are the treatment of choice which can be used for hypercholesterolemia and primary prevention of cardiovascular and cerebrovascular disease. In our case report, we demonstrated the improvement in total cholesterol and LDL cholesterol levels to target with use of the PCSK9 inhibitor, evolocumab.
CONCLUSION
In conclusion, NAM is a rare side-effect of statin therapy and is increasingly being recognized within the "statin-induced myopathy" spectrum. Exclusion of more common autoimmune myopathic conditions, metabolic, and neurologic causes of proximal lower limb myopathy or neuropathy is essential for diagnosis of NAM. This condition should be included in the differential diagnosis of persistent myopathy and CK elevation in statin-exposed individuals, particularly despite statin discontinuation. NAM necessitates a prompt diagnosis as immunosuppressive therapy is warranted and statin therapy is contraindicated. PCSK9 inhibitors are the agents of choice for treatment of hypercholesterolemia and cardiovascular/cerebrovascular protection in patients who have a statin contraindication. Further studies are important to identify which individuals are at risk for developing statin-induced NAM, for whom statin therapy should be avoided altogether.
